GKGalina Yu. Kharkevich

Galina Yu. Kharkevich

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Galina Yu. Kharkevich has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Changes in clinical guidelines of 2023 and 2025 on treatment of cutaneous and mucosal melanoma

    by I. V. Samoylenko, Ya. V. Belenkaya, M. E. Abramov, M. D. Aliev, S. M. Banov, T. S. Belysheva, G. I. Gafton, A. V. Golanov, L. V. Demidov, N. V. Zhukova, et al.

    The article presents a comparative analysis of Russian clinical recommendations on treatment of melanoma of the skin and mucous membranes during a period of 2020 and 2023, as well as foreign recommendations of N CCN (National Comprehensive Cancer Network) and ESMO (European Society for Medical Oncology) of 2025. The main debatable issues related to changes on melanoma therapy in 2025 are presented for discussion. The topic of modifying the treatment of patients with melanoma with metastases in the brain is highlighted. New treatment options for patients with metastatic and unresectable (stage IIIC–D) melanoma are discussed, as well as the neoadjuvant and adjuvant therapy options for stage II–III cutaneous melanoma. Various treatment options for patients with local stage melanoma are considered. Among other, the recommendations of 2025 are supplemented with treatment options for melanoma in children.Aim. To highlight changes in clinical guidelines for treatment of melanoma of the skin and mucous membranes for use in daily clinical practice.


  • Open Access

    Serologic predictors of thyroid immune-related adverse events during immune checkpoint inhibitors therapy: a retrospective cohort study

    by Anastasia A. Glibka, Natalia V. Mazurina, Ksenia A. Sarantseva, Galina Y. Kharkevich, Mikhail V. Volkonskii, Alina R. Elfimova, Ekaterina A. Troshina, Саранцева Ксения Андреевна, Харкевич Галина Юрьевна, Волконский Михаил Викторович

    Rationale: Immune-related adverse events (irAEs) are a specific type of drug toxicity that can occur in cancer patients undergoing immunotherapy with immune checkpoint inhibitors (ICIs). Endocrine irAEs rank the 3rd after the skin and gastrointestinal ones. Clinical course of endocrine irAEs usually results in irreversible damage of the glands function. Prevailing thyroid disorders among endocrine irAEs, their reactivity compared to that of autoimmune thyroiditis, the risk of potential temporary or complete withdrawal of the immunotherapy would make it necessary to search for markers able to identify the most susceptible patient groups. Aim: To evaluate an association between baseline laboratory parameters (hormonal, biochemical, and serological) in patients with malignant solid neoplasms before the first course of anti-tumor immunotherapy with ICIs in monotherapy and the subsequent development of thyroid irAEs. Methods: In this retrospective cohort we analyzed medical files from 102 adult patients (50 (49%) men, median age 60 years) with confirmed solid malignant tumors who were treated in two specialized in-patient departments from January 2020 to February 2022. Their baseline blood samples for subsequent evaluation of thyroid function, carbohydrate and calcium metabolism, as well as to exclude adrenal insufficiency were taken before the initiation of the first course of specific immunotherapy with ICIs. Thereafter, the patients were monitored for any registered irAE for up to 34 months from the beginning of the antitumor immunotherapy with ICIs. Results: Thyroid irAEs were registered in 13/102 (12.7%) patients. Only two markers were significantly associated with the development of thyroid disorders under immunotherapy with ICIs: baseline levels of anti-thyroperoxidase antibodies (TPOAb) ≥ 7.54 IU/mL (reference range (RR) 0–5.6) and anti-thyroglobulin antibodies (TgAb) ≥ 16.45 IU/mL (RR 0–115) (p 0.001). For TPOAb ≥ 7.54 IU/mL and TgAb ≥ 16.45 IU/mL, the areas under the ROC curve (AUC) were 0.828 [95% confidence interval (CI) 0.678–0.979] and 0.875 [95% CI 0.742–1.000], diagnostic sensitivity was 75% [95% CI 48–92] and 92% [95% CI 64–100], diagnostic specificity 92% [95% CI 85–96] and 84% [95% CI 77–86], prognostic values of the positive result 69% [95% CI 44–85] and 58% [95% CI 40–63], and prognostic values of the negative results 94% [95% CI 87–98] and 98% [95% CI 90–100], respectively. Conclusion: Baseline levels of TPOAb and TgAb may serve as markers for the risk of thyroid irAEs in cancer patients with solid malignancies who are planned to receive anti-tumor immunotherapy with ICIs.


  • Open Access

    Prognostic value of gene expression profiling in melanoma: a systematic literature review

    by I. V. Samoilenko, Ya. V. Belenkaya, G. Yu. Kharkevich, K. V. Orlova, I. N. Mikhailova, K. A. Baryshnikov, Ya. V. Vishnevskaya, L. V. Demidov

    Introduction. Skin melanoma, despite having similar clinical and histological characteristics, can have different prognoses. Gene expression profiling potentially allows for more accurate risk stratification of patients.Aim. To study prognostic test systems for assessing outcomes in patients with skin melanoma based on the analysis of primary tumors.Materials and methods. A systematic literature review (scoping review) was conducted in accordance with PRISMA-ScR principles. The search was performed in PubMed (2008–2024). Two independent reviewers conducted the study selection and data analysis to assess concordance. The data were presented descriptively.Results. Out of 149 identified publications, 31 studies were included in the review. The effectiveness of four test systems was evaluated, with the most frequently used being DecisionDx-Melanoma (19/31, 61.3%). This test stratifies patients by molecular classes: patients at high risk were found to have a 5.33 (±1.25) times higher likelihood of disease progression and poorer survival rates compared to lower-risk patients. No studies included data on the Russian population.Conclusions. Gene expression profiling demonstrates high accuracy in predicting outcomes for patients with skin melanoma.

  • Open Access

    Body mass index as a possible predictor of the development of endocrine immune-mediated adverse events during immune checkpoint inhibitors therapy

    by A. A. Glibka, N. V. Mazurina, E. A. Troshina, K. A. Sarantseva, G. Yu. Kharkevich, M. V. Volkonskii, A. R. Elfimova, Г. Ю. Харкевич

    BACKGROUND: Overweight and obesity have a significant impact on the course and results of treatment of many diseases, including cancer. One of the modern types of antitumor therapy is immune checkpoint inhibitors. Taking into account the high effectiveness of immune checkpoint inhibitors for various types of tumors, it seems interesting to study the initial anthropometric data of patients and assess the possible influence of nutritional status on the development of endocrine immune-mediated adverse events.AIM: To compare groups of patients with different starting body mass index (BMI) before the first administration of the immune checkpoint inhibitors drug and analyze the risk of developing endocrine immune-mediated adverse events in the future.MATERIALS AND METHODS: The single-center study included 172 patients who were recommended antitumor therapy immune checkpoint inhibitors at the N.N. Blokhin National Medical Research Center of Oncology and Moscow City Oncology Hospital №62 in 2020–2022. Measurement of height and body weight with further calculation of BMI was carried out before the first administration of the drug immune checkpoint inhibitors.Depending on the subsequent occurrence of immune-mediated adverse events, patients were divided into groups: those with developed immune-mediated adverse events (any, cutaneous, thyroid) and those without immune-mediated adverse events (any, cutaneous, thyroid).RESULTS: According to the results of our study, in 38 patients (37.3%) out of 102, for whom data on the presence/absence of any immune-mediated adverse events were obtained, the following were recorded: thyropathies (n=13, 12.7%), skin lesions (n=13, 12.7%), gastrointestinal toxicity (n=7, 6.9%), hepatotoxicity (n=4, 3.9%), hypophysitis (n=2, 2%), nephritis (n=2, 2%), diabetes mellitus (DM) (n=1, 1%), hematological toxicity (n=1, 1%), pneumonitis (n=1, 1%), Guillain-Barré syndrome (n=1, 1%). At the same time, in most patients only one immune-mediated adverse event was encountered (n=31, 81.6%), two immune-mediated adverse events were detected significantly less frequently (n=7, 18.4%).When conducting a comparative analysis of groups of patients with developed immune-mediated adverse events, including dermatological ones, or their absence, a statistical trend in differences in BMI was obtained. Using ROC analysis, a BMI cut-off point was determined equal to 28.16 kg/m² for all immune-mediated adverse events and 25.39 kg/m² for skin immune-mediated adverse events, below which, contrary to the available data, the risk of developing immune-mediated adverse events increased, but the diagnostic sensitivity (DS) and diagnostic specificity (DS) turned out to be low.CONCLUSION: We identified a statistical trend in the risk of developing immune-mediated adverse events (primarily dermatological) with a lower BMI before the start of antitumor immunotherapy immune checkpoint inhibitors. More research is required to find a more reliable relationship.


  • Open Access

    Thyroid disorders induced by immune checkpoint inhibitors therapy of malignant tumors

    by Anastasiya A. Glibka, Natalya V. Mazurina, Ksenia A. Sarantseva, Galina Y. Kharkevich, Konstantin K. Laktionov, Ekaterina A. Troshina, Galina A. Mel`nIchenko, Саранцева Ксения Андреевна, Харкевич Галина Юрьевна

    In the recent years, immune checkpoint inhibitors (ICPI) have been widely used for treatment of many malignant neoplasms. In the Russian Federation, several ICPIs have been approved and actively used, namely anti-CTLA-4 monoclonal antibody (ipilimumab), anti-PD-1 monoclonal antibodies (nivolumab, pembrolizumab, prolgolimab), and anti-PD-L1 monoclonal antibodies (atezolizumab, durvalumab). ICPIs may cause various endocrine immune-mediated adverse events, most commonly thyroid dysfunction and hypophysitis, which are at large associated with anti-tumor therapy with a certain subgroup of these agents. Predictors of endocrine immune-mediated adverse events remain unclear, and their optimal prevention, prediction and treatment have not been yet defined. The review contains the information accumulated in the literature on the mechanisms, biomarkers, specific characteristics of thyroid immune-mediated adverse events and describes the principles of treatment for these thyroid disorders. This information would be useful for practicing oncologists, endocrinologists, internists, family physicians, as well as for any other medical specialties.


  • Open Access

    Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE)

    by Kristina V. Orlova, Evgeniy V. Ledin, Natalia V. Zhukova, Rashida V. Orlova, Elena V. Karabina, Mikhail V. Volkonskiy, Daniil L. Stroyakovskiy, Aleksandr N. Yurchenkov, Svetlana A. Protsenko, Alexey V. Novik, et al.

    Clinical trials of targeted therapy (TT) and immunotherapy (IT) for highly aggressive advanced melanoma have shown marked improvements in response and survival rates. However, real-world data on treatment patterns and clinical outcomes for patients with advanced BRAF V600 mutant melanoma are ultimately scarce. The study was designed as an observational retrospective chart review study, which included 382 patients with advanced BRAF V600 mutant melanoma, who received TT in a real-world setting and were not involved in clinical trials. The data were collected from twelve medical centers in Russia. The objective response rates (ORRs) to combined BRAFi plus MEKi and to BRAFi mono-therapy were 57.4% and 39.8%, respectively. The median progression-free survival (PFS) and median overall survival (OS) were 9.2 months and 22.6 months, respectively, for the combined first-line therapy; 9.4 months and 16.1 months, respectively, for the combined second-line therapy; and 7.4 months and 17.1 months, respectively, for the combined third- or higher-line therapy. Analysis of treatment patterns demonstrated the effectiveness of the combined TT with BRAF plus MEK inhibitors in patients with brain metastases, rare types of BRAF mutations, and across lines of therapy, as well as a well-tolerated and manageable safety profile.


  • Open Access

    Development of destructive thyroiditis and diabetes mellitus after three injections of pembrolizumab for skin melanoma

    by A. A. Glibka, G. A. Mel`nIchenko, M. S. Mikhina, N. V. Mazurina, G. Yu. Kharkevich, Г. Ю. Харкевич

    The exponential rise in the use of immune checkpoint inhibitors (Ipilimumab, Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab, and Avelumab) as the new standard for cancer treatment increase the incidence the immune-related adverse events due to immune activation. Endocrine immune-related adverse events are the third most commonly reported. Thyroid gland is most susceptible to autoimmune dysfunctions from immune checkpoint inhibitors and associated with the use of anti-PD-1 monoclonal antibodies. Hypophysitis develops more often during therapy with anti-CTLA-4 monoclonal antibodies. But such immune-related adverse events as diabetes mellitus, hypoparathyroidism are rare (about 1% of cases).We present a clinical case of the patient with skin melanoma who was prescribed therapy with immune checkpoints inhibitors (Pembrolizumab). Immune-related adverse events developed with damage to the endocrine organs after 3 Pembrolizumab injections. Of greatest interest is the development of two endocrine immune-related adverse events at once: destructive thyroiditis (with a short phase of thyrotoxicosis and subsequent persistent hypothyroidism) and diabetes mellitus. We tried to reflect the chronology of diseases and their features as fully as possible for endocrinologists, oncologists, therapists, family doctors and other medical doctors of related specialties.


  • Open Access

    Эффективность ниволумаба в лечении метастатической меланомы

    by G. Y. Kharkevich, L. V. Demidov, Г. Ю. Харкевич

    Эффективность ниволумаба в лечении метастатической меланомы